XAIR

Beyond Air, Inc. (XAIR) - Q2 2024 10-Q Summary

Business Context and Reporting Period

This summary covers the quarterly period ended September 30, 2024. Beyond Air, Inc. is a commercial-stage medical device and biopharmaceutical company developing the LungFit® platform, which generates nitric oxide (NO) from ambient air. The company's primary commercial product, LungFit® PH, received FDA approval in June 2022 for treating persistent pulmonary hypertension of the newborn (PPHN). The company also operates two development segments: Beyond Cancer (solid tumors) and a neurological program targeting autism spectrum disorder (ASD).

Key Financial Metrics

Note: The company reported a gross loss of $1.1 million for the quarter and $1.4 million for the six-month period due to high costs of revenue relative to sales.

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased significantly from $0.2 million in Q2 2023 to $0.8 million in Q2 2024, driven by expanding hospital contracts for LungFit® PH.
• Expense Reduction: Operating expenses decreased by approximately $5.6 million year-over-year for the quarter, primarily due to reduced stock-based compensation and lower R&D spend.
• Debt Restructuring: The company reached an agreement to extinguish its senior secured term loan with Avenue Capital for a one-time payment of $17.85 million (partially paid in Q2, final payment in October 2024), eliminating future interest obligations.
• Capital Raise: In late September 2024, the company closed a private placement (Securities Purchase Agreement II) raising gross proceeds of $20.6 million ($18.9 million net) through the sale of common stock, pre-funded warrants, and warrants.
• Stock-Based Compensation: Stock-based compensation expense dropped from $6.5 million in the prior six-month period to $6.5 million in the current period, though the quarterly run rate decreased significantly due to workforce reductions.

Guidance, Outlook, and Risks

• Liquidity Concerns: Management explicitly states that factors such as accumulated losses of $265.3 million and cash burn raise substantial doubt about the company's ability to meet obligations with cash on hand. However, management believes this is alleviated by recent capital raises and cost-cutting measures.
• Capital Conservation: The company has implemented a strategy reducing staffing levels by over 30%, placing the VCAP (viral pneumonia) clinical study on hold pending funding, and adjusting production forecasts.
• New Financing: A new secured loan agreement was finalized in November 2024 for $11.5 million with a 10-year term, 15% interest (payable in kind initially), and an 8% royalty on net sales.
• Nasdaq Compliance: The company received notice from Nasdaq regarding non-compliance with the $1.00 minimum bid price requirement. It has 180 days (until February 4, 2025) to regain compliance, potentially via a reverse stock split.
• Commercial Outlook: The company expects to receive CE mark certification in the EU in the second half of 2024 and aims to expand commercial presence in the U.S. and globally.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $28.4 million cash balance against the $23.5 million operating cash burn rate for the first six months of the year.
• Debt Obligations: Confirm the terms and repayment schedule of the new $11.5 million loan and the impact of the 8% royalty on future net sales.
• Warrant Dilution: Assess the dilution impact of the 82 million outstanding warrants, many of which have low exercise prices ($0.38 or $0.0001) but require shareholder approval for exercise.
• Nasdaq Status: Monitor the company's progress in meeting the $1.00 minimum bid price requirement to avoid delisting.
• Revenue Sustainability: Evaluate the durability of the revenue growth from LungFit® PH leases and the timeline for profitability given the current gross loss.